EDENBRIDGE PHARMS FDA Approval NDA 215019

NDA 215019

EDENBRIDGE PHARMS

FDA Drug Application

Application #215019

Documents

Label2021-12-17
Letter2021-12-21

Application Sponsors

NDA 215019EDENBRIDGE PHARMS

Marketing Status

Prescription001

Application Products

001TABLET;ORALLY DISINTEGRATING1.7MG0DARTISLA ODTGLYCOPYRROLATE

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2021-12-16STANDARD

Submissions Property Types

ORIG1Null15

CDER Filings

EDENBRIDGE PHARMS
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 215019
            [companyName] => EDENBRIDGE PHARMS
            [docInserts] => ["",""]
            [products] => [{"drugName":"DARTISLA ODT","activeIngredients":"GLYCOPYRROLATE","strength":"1.7MG","dosageForm":"TABLET;ORALLY DISINTEGRATING","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
            [labels] => [{"actionDate":"12\/16\/2021","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/215019s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"12\/16\/2021","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/215019s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2021\\\/215019Orig1s000ltr.pdf\"}]","notes":">"}]
            [supplements] => 
            [actionDate] => 2021-12-16
        )

)

© 2022 FDA.report
This site is not affiliated with or endorsed by the FDA.